Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Stewart

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
AJR. American Journal of Roentgenology|November 18, 2004
MRI guidance of focused ultrasound therapy of uterine fibroids: early resultsJonathan Hindley, Wladyslaw M Gedroyc, Lesley Regan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2015
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in OsteosarcomaAnkita Gupte, Emma K Baker, Soo-San Wan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2021
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322AWayne L Furman, Beth McCarville, Barry L Shulkin, et al.
Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.
Journal of Clinical Medicine|April 30, 2021
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task ForceHolly L Pacenta, Wendy Allen-Rhoades, David Langenau, et al.
Cell Reports|December 2, 2014
Targeting the DNA repair pathway in Ewing sarcomaElizabeth Stewart, Ross Goshorn, Cori Bradley, et al.
Nature|August 31, 2017
Orthotopic patient-derived xenografts of paediatric solid tumoursElizabeth Stewart, Sara M Federico, Xiang Chen, et al.
Nature Communications|February 28, 2025
Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acidMin Pan, Yinwen Zhang, William C Wright, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acidMin Pan, Yinwen Zhang, William C Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2019
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk NeuroblastomaWayne L Furman, Sara M Federico, Mary Beth McCarville, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
AJR. American Journal of Roentgenology|November 18, 2004
MRI guidance of focused ultrasound therapy of uterine fibroids: early resultsJonathan Hindley, Wladyslaw M Gedroyc, Lesley Regan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2015
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in OsteosarcomaAnkita Gupte, Emma K Baker, Soo-San Wan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2021
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322AWayne L Furman, Beth McCarville, Barry L Shulkin, et al.
Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.
Journal of Clinical Medicine|April 30, 2021
Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task ForceHolly L Pacenta, Wendy Allen-Rhoades, David Langenau, et al.
Cell Reports|December 2, 2014
Targeting the DNA repair pathway in Ewing sarcomaElizabeth Stewart, Ross Goshorn, Cori Bradley, et al.
Nature|August 31, 2017
Orthotopic patient-derived xenografts of paediatric solid tumoursElizabeth Stewart, Sara M Federico, Xiang Chen, et al.
Nature Communications|February 28, 2025
Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acidMin Pan, Yinwen Zhang, William C Wright, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acidMin Pan, Yinwen Zhang, William C Wright, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2019
A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk NeuroblastomaWayne L Furman, Sara M Federico, Mary Beth McCarville, et al.
Pageof 14